Isonics Unveils New ``Tarant 1'' Mobile Product Platform; Designed to Transport Isonics' NeutroTest to Keep Operators at a Safe Distance from Potential Threats

The Tarant 1 is the result of a joint development effort betweenIsonics and Scaled Robotics, Inc., of Corona del Mar, California. TheTarant 1, which resembles a space-age moon crawler on three wheels, isabout 20 inches long, by 20 inches wide, by 8 inches high (withoutpayload) and can maneuver effectively over multi-terrain surfaces atspeeds up to 5 to 10 miles per hour.

"The ability to keep the operator out of harm's way while lookingfor improvised explosive devices (IEDs) and other dangerous materialsis a logical improvement," commented James E. Alexander, Isonics'Chairman & CEO. "Not only does Tarant 1 potentially achieve this butprovides extended range and flexibility for our hand-held detectionproducts."

"In addition to carrying Isonics detection instruments, the Tarant1 can be customized with daylight or night vision cameras, or otherthird-party technology depending on the specific mission," said theprototype's lead designer, Richard Rice, CEO of Scaled Robotic Inc.(SRI) "It operates on wireless remote control or can be configured forline control in RF sensitive areas."

Isonics is prepared to start accepting orders for the Tarant 1immediately for first calendar quarter 2006 delivery. Tarant 1 will beavailable either equipped with Isonics detection instruments or can beprovided configured for transport of third-party products.

Pursuant to the agreement between Isonics and Scaled Robotics,Isonics has obtained a 10% equity interest in SRI and has options toincrease its ownership in SRI up to 45%. If Isonics exercises all ofits options, it will also receive exclusive rights to purchase, marketand sell any and all products which SRI may now or in the futureproduce. For additional information on the Tarant 1, including a .pdffile "Spec Sheet.", please visit:http://www.trilogy-capital.com/isonics/tarant.aspx

About Isonics Corporation

Isonics Corporation has three business divisions: (1) IsonicsSemiconductor, (2) Isonics Life Sciences, and (3) Homeland Securityand Defense. Isonics is a world leader in isotopically engineeredmaterials and through its semiconductor division produces isotopicallypure silicon-28 chemicals, silicon-on-insulator wafers, wafer-reclaimservices and test wafers, including 300mm, for the semiconductorindustry. Isonics' Life Sciences division markets and sells isotopesto the health care industry for the imaging and treatment of cancer.Stable isotopes can be thought of as ultra pure materials. This highdegree of purification provides enhanced properties as compared tonatural materials. Our efforts in the Homeland Security segment arenascent at the present time as we proceed to develop further ourneutron-based detection technologies. Additional information may beobtained at the Company's Web site at www.isonics.com and athttp://www.trilogy-capital.com/tcp/isonics. A presentation aboutIsonics' NeutroTest(TM) explosive detection prototype can be found athttp://www.trilogy-capital.com/tcp/isonics/presentation.html. A videodemonstrating the functioning NeutroTest prototype can be viewed athttp://www.trilogy-capital.com/tcp/isonics/video.html.

Cautionary Statement

Except for historical information contained herein, this documentcontains forward-looking statements within the meaning of the PrivateSecurities Litigation Reform Act of 1995. These statements involveknown and unknown risks and uncertainties that may cause the Company'sactual results or outcomes to be materially different from thoseanticipated and discussed herein. Further, the Company operates inindustries where securities values may be volatile and may beinfluenced by regulatory and other factors beyond the Company'scontrol. Other important factors that the Company believes might causesuch differences are discussed in the risk factors detailed in theCompany's 10-KSB for the year ended April 30, 2005, as filed with theSecurities and Exchange Commission, which include the Company'shistorical cash flow difficulties, dependence on significantcustomers, and rapid development of technology, among other risks. Inassessing forward-looking statements contained herein, readers areurged to carefully read all cautionary statements contained in theCompany's filings with the Securities and Exchange Commission. Isonicscautions investors that it has had only limited sales of itsNeutroTest products and has made no NeutroTest sales to any governmentagency. There can be no assurance that Isonics will be able tomanufacture significant quantities of NeutroTest products for themarket at a cost and with capabilities that meet the needs ofprospective customers.

This announcement may contain forward-looking statements made bysenior management of Isonics that involve risks and uncertainties,such as statements about plans, objectives, expectations, assumptionsor future events. These statements involve estimates, assumptions,known and unknown risks, uncertainties and performances, orachievements expressed or implied by the forward-looking statements.Actual future results and trends may differ materially from those madein, or suggested by, statements made in this announcement due to avariety of factors. Consequently, you should not place undue relianceon any forward-looking statements made in this announcement. For moreinformation about Isonics and risks arising from investing in Isonics,you are directed to the Company's most recent Form 10-KSB filed withthe Securities and Exchange Commission.